Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...
Stocktwits on MSN
BEAM stock in focus as FDA alignment wins William Blair’s praise
The company expects to submit a biologics license application for risto-cel by year-end 2026. ・Beam ended 2025 with an ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
Under the proposed changes, 10 schools will lose some programs of study. Instead, students will have access to 16 courses at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback